Spatial Gradients of E-Cadherin and Fibronectin in TGF-β1-Treated Epithelial Colonies Are Independent of Fibronectin Fibril Assembly.
TGF-β1
epithelial mesenchymal transition
fibronectin
micropatterning
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 Apr 2023
03 Apr 2023
Historique:
received:
13
02
2023
revised:
24
03
2023
accepted:
30
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Epithelial to Mesenchymal Transition (EMT) is a dynamic, morphogenetic process characterized by a phenotypic shift in epithelial cells towards a motile and often invasive mesenchymal phenotype. We have previously demonstrated that EMT is associated with an increase in assembly of the extracellular matrix protein fibronectin (FN) into insoluble, viscoelastic fibrils. We have also demonstrated that Transforming Growth Factor-β1 (TGF-β1) localizes to FN fibrils, and disruption of FN assembly or disruption of TGF-β1 localization to FN fibrils attenuates EMT. Previous studies have shown that TGF-β1 induces spatial gradients of EMT in mammary epithelial cells cultured on FN islands, with cells at free edges of the island preferentially undergoing EMT. In the current work, we sought to investigate: (a) whether FN fibril assembly is also spatially patterned in response to TGF-β1, and (b) what effects FN fibril inhibition has on spatial gradients of E-Cadherin and FN fibrillogenesis. We demonstrate that mammary epithelial cells cultured on square micropatterns have fewer E-Cadherin-containing adherens junctions and assemble more FN fibrils at the periphery of the micropattern in response to increasing TGF-β1 concentration, indicating that TGF-β1 induces a spatial gradient of both E-Cadherin and FN fibrils. Inhibition of FN fibril assembly globally diminished E-Cadherin-containing adherens junctions and FN fibrillogenesis, but did not eliminate the spatial gradient of either. This suggests that global inhibition of FN reduces the degree of both FN fibrillogenesis and E-Cadherin-containing adherens junctions, but does not eliminate the spatial gradient of either, suggesting that spatial gradients of EMT and FN fibrillogenesis are influenced by additional factors.
Identifiants
pubmed: 37047651
pii: ijms24076679
doi: 10.3390/ijms24076679
pmc: PMC10095504
pii:
doi:
Substances chimiques
Transforming Growth Factor beta1
0
Fibronectins
0
Cadherins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIGMS NIH HHS
ID : F31 GM121035
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM122855
Pays : United States
Organisme : NIGMS NIH HHS
ID : F31GM121035
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01GM122855
Pays : United States
Références
Biomaterials. 2022 Feb;281:121337
pubmed: 34979418
Integr Biol (Camb). 2010 Sep;2(9):424-34
pubmed: 20717570
MethodsX. 2019 May 31;6:1343-1352
pubmed: 31417850
Adv Drug Deliv Rev. 2021 Mar;170:353-368
pubmed: 32961203
J Biol Chem. 2005 May 13;280(19):18871-80
pubmed: 15677465
J Bone Miner Res. 2000 Jan;15(1):68-81
pubmed: 10646116
Curr Top Dev Biol. 2018;130:1-37
pubmed: 29853174
Dev Cell. 2019 May 6;49(3):313-316
pubmed: 31063750
Methods Cell Biol. 2014;120:93-116
pubmed: 24484659
Integr Biol (Camb). 2015 Nov;7(11):1454-65
pubmed: 26412391
Tissue Eng. 2004 May-Jun;10(5-6):865-72
pubmed: 15265304
FASEB J. 2010 Dec;24(12):4711-21
pubmed: 20671107
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Curr Rheumatol Rep. 2018 Jan 19;20(1):2
pubmed: 29349703
J Biol Chem. 2001 Jun 29;276(26):23430-9
pubmed: 11323441
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5139-43
pubmed: 11959962
Annu Rev Cell Dev Biol. 2011;27:347-76
pubmed: 21740232
FASEB J. 2005 Nov;19(13):1798-808
pubmed: 16260650
J Cell Biochem. 2010 May;110(1):44-51
pubmed: 20336666
J Cell Physiol. 2012 Dec;227(12):3828-36
pubmed: 22495824
Cells. 2021 Sep 16;10(9):
pubmed: 34572092
Biomed Pharmacother. 2021 Jan;133:110909
pubmed: 33227701
Cancers (Basel). 2021 Feb 09;13(4):
pubmed: 33572395
J Vis Exp. 2019 Jun 1;(148):
pubmed: 31205302
J Cell Biol. 1998 Apr 20;141(2):539-51
pubmed: 9548730
Matrix Biol. 2017 Jul;60-61:157-175
pubmed: 28109697
Front Cell Dev Biol. 2019 Jul 19;7:135
pubmed: 31380370
Biomech Model Mechanobiol. 2020 Dec;19(6):1997-2013
pubmed: 32193709
Cells. 2019 Sep 20;8(10):
pubmed: 31547193
J Clin Invest. 2003 Dec;112(12):1776-84
pubmed: 14679171
Mol Biol Cell. 2012 Mar;23(5):781-91
pubmed: 22238361
Biophys J. 2009 Jan;96(2):729-38
pubmed: 19167317
Matrix Biol. 2017 Dec;64:69-80
pubmed: 28602859
Methods Cell Biol. 2014;121:33-48
pubmed: 24560501
Mol Biol Cell. 2017 Apr 15;28(8):1043-1053
pubmed: 28228548
Oncogene. 2014 Mar 27;33(13):1649-57
pubmed: 23624917